Results 91 to 100 of about 6,578,993 (340)
Multiple myeloma current treatment algorithms
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy.
S. Rajkumar, Shaji K. Kumar
semanticscholar +1 more source
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng +19 more
wiley +1 more source
The non-coding RNA landscape of plasma cell dyscrasias [PDF]
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A +3 more
core +1 more source
Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B +6 more
core +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho +7 more
doaj +1 more source
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting.
S. Ito
semanticscholar +1 more source
ABSTRACT Triple‐negative breast cancer (TNBC) exhibits addiction to chronic endoplasmic reticulum (ER) stress, which sustains an aggressive metastatic phenotype through activation of the unfolded protein response (UPR). Here, we identify a previously unrecognized “ER‐stress addiction” axis in which the Hippo pathway effector TEAD4 directly ...
Yini Shang +9 more
wiley +1 more source
Multiple Myeloma in Indonesia [PDF]
Tujuan: Melihat karakteristik klinis pasien mieloma multipel di Indonesia.Metode: studi deskriptif, potong lintang, multisenter, dilakukan pada November 2008 sampai dengan November 2009.
Reksodiputro, A. H. (Arry) +2 more
core
A metastatic secretory gastric plasmacytoma with aberrant CD3 expression in a dog [PDF]
A 10-year-old crossbred dog was presented with a 6-week history of hematemesis, melena, anorexia, and lethargy. Clinical evaluation revealed a gastric mass with a regional lymphadenomegaly as well as a monoclonal gammopathy manifesting as ...
Atherton, Matthew J. +4 more
core +1 more source

